晚期结直肠癌治疗：ASCO资源分层指南 2020

美国临床肿瘤学会 JCO

近日，《晚期结直肠癌治疗：ASCO资源分层指南》发表在JCO Glob Oncol杂志，该指南旨在为临床医生、公共卫生领导者和所有资源条件下的决策者提供晚期结直肠癌治疗的专业指导。目标人群为晚期结直肠

中文标题：

英文标题：

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

发布机构：

美国临床肿瘤学会

发布日期：

简要介绍：

近日，《晚期结直肠癌治疗：ASCO资源分层指南》发表在JCO Glob Oncol杂志，该指南旨在为临床医生、公共卫生领导者和所有资源条件下的决策者提供晚期结直肠癌治疗的专业指导。目标人群为晚期结直肠癌患者——转移性TNM分期：T、N、M1或不可切除TNM分期：T、N、M0结直肠癌。

世界各国以及各国的不同地区在结直肠癌的早期检测方面存在差异。许多地区没有进行大规模或甚至进行机会性筛查，即使在进行大规模筛查的某些地区，部分人群也可能无法进行筛查。基于此，ASCO资源分层指南咨询小组制定了按资源分层的晚期结直肠癌治疗指南。在制定该指南时，ASCO采用了四层资源设置方法（基础资源、有限资源、改善资源、最大化资源[最初由“乳房健康全球倡议”制定]）并基于疾病控制优先级进行了修改，本指南总结了指南制定的结果，提出了按资源分层晚期结直肠癌的治疗建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=0b0011c001899a3c, title=晚期结直肠癌治疗：ASCO资源分层指南 2020, enTitle=Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline, guiderFrom=JCO, authorId=0, author=, summary=近日，《晚期结直肠癌治疗：ASCO资源分层指南》发表在JCO Glob Oncol杂志，该指南旨在为临床医生、公共卫生领导者和所有资源条件下的决策者提供晚期结直肠癌治疗的专业指导。目标人群为晚期结直肠, cover=, journalId=0, articlesId=null, associationId=8, associationName=美国临床肿瘤学会, associationIntro=美国临床肿瘤学会（ASCO，American Society of Clinical Oncology）是一个成立于1964年的非营利性组织，总目标是改善肿瘤的监护与预防。目前已有27000名肿瘤科医师加入了ASCO，分属各个肿瘤专科和亚专科。会员包括在肿瘤治疗各个层次的医师和卫生保健专业人员。ASCO由一个有19名成员的当选董事会管理，该学会的大部分业务是由志愿为学会项目花费时间和出力的ASCO会员组成的各种委员会处理的。患者支持团体的领导也经常活跃于ASCO委员会中。目前有22个由ASCO的全职人员管理和支持的委员会。, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<section>近日，《晚期结直肠癌治疗：ASCO资源分层指南》发表在JCO Glob Oncol杂志，该指南旨在为临床医生、公共卫生领导者和所有资源条件下的决策者提供晚期结直肠癌治疗的专业指导。目标人群为晚期结直肠癌患者——转移性TNM分期：T、N、M1或不可切除TNM分期：T、N、M0结直肠癌。</section> <section></section> <section>世界各国以及各国的不同地区在结直肠癌的早期检测方面存在差异。许多地区没有进行大规模或甚至进行机会性筛查，即使在进行大规模筛查的某些地区，部分人群也可能无法进行筛查。基于此，ASCO资源分层指南咨询小组制定了按资源分层的晚期结直肠癌治疗指南。在制定该指南时，ASCO采用了四层资源设置方法（基础资源、有限资源、改善资源、最大化资源[最初由“乳房健康全球倡议”制定]）并基于疾病控制优先级进行了修改，本指南总结了指南制定的结果，提出了按资源分层晚期结直肠癌的治疗建议。</section> <section></section>, tagList=[TagDto(tagId=539, tagName=结直肠癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=5, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1827, appHits=233, showAppHits=15, pcHits=403, showPcHits=1594, likes=0, shares=8, comments=6, approvalStatus=1, publishedTime=Fri Jan 29 15:07:13 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Fri May 01 17:25:10 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 21:24:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=JGO.19.00367.pdf)])

JGO.19.00367.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1055270, encodeId=c41b10552e0ac, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:57:37 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006844, encodeId=fe73100684449, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:04:54 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006840, encodeId=a7c41006840fa, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:03:24 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977322, encodeId=61ba9e7322f3, content=有用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/bfd172f9945c40638fb6690b2055104f/11dc30fbfd9b43328a224b891e909299.jpg, createdBy=324f5523472, createdName=ms2550785022369385, createdTime=Sun Jun 27 14:44:24 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976956, encodeId=af499e6956c6, content=学习了，有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:25:47 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
2021-09-27 病友

非常棒

88 0
[GetPortalCommentsPageByObjectIdResponse(id=1055270, encodeId=c41b10552e0ac, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:57:37 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006844, encodeId=fe73100684449, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:04:54 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006840, encodeId=a7c41006840fa, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:03:24 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977322, encodeId=61ba9e7322f3, content=有用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/bfd172f9945c40638fb6690b2055104f/11dc30fbfd9b43328a224b891e909299.jpg, createdBy=324f5523472, createdName=ms2550785022369385, createdTime=Sun Jun 27 14:44:24 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976956, encodeId=af499e6956c6, content=学习了，有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:25:47 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
2021-08-11 ms2000000518920136

好文

90 0
[GetPortalCommentsPageByObjectIdResponse(id=1055270, encodeId=c41b10552e0ac, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:57:37 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006844, encodeId=fe73100684449, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:04:54 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006840, encodeId=a7c41006840fa, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:03:24 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977322, encodeId=61ba9e7322f3, content=有用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/bfd172f9945c40638fb6690b2055104f/11dc30fbfd9b43328a224b891e909299.jpg, createdBy=324f5523472, createdName=ms2550785022369385, createdTime=Sun Jun 27 14:44:24 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976956, encodeId=af499e6956c6, content=学习了，有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:25:47 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
2021-08-11 ms2000000518920136

好文

110 0
[GetPortalCommentsPageByObjectIdResponse(id=1055270, encodeId=c41b10552e0ac, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:57:37 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006844, encodeId=fe73100684449, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:04:54 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006840, encodeId=a7c41006840fa, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:03:24 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977322, encodeId=61ba9e7322f3, content=有用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/bfd172f9945c40638fb6690b2055104f/11dc30fbfd9b43328a224b891e909299.jpg, createdBy=324f5523472, createdName=ms2550785022369385, createdTime=Sun Jun 27 14:44:24 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976956, encodeId=af499e6956c6, content=学习了，有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:25:47 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
2021-06-27 ms2550785022369385

有用

100 0
[GetPortalCommentsPageByObjectIdResponse(id=1055270, encodeId=c41b10552e0ac, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4615618805, createdName=病友, createdTime=Mon Sep 27 09:57:37 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006844, encodeId=fe73100684449, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:04:54 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006840, encodeId=a7c41006840fa, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51a75569871, createdName=ms2000000518920136, createdTime=Wed Aug 11 08:03:24 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977322, encodeId=61ba9e7322f3, content=有用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/bfd172f9945c40638fb6690b2055104f/11dc30fbfd9b43328a224b891e909299.jpg, createdBy=324f5523472, createdName=ms2550785022369385, createdTime=Sun Jun 27 14:44:24 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976956, encodeId=af499e6956c6, content=学习了，有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66b75534476, createdName=ms6000000079288216, createdTime=Sat Jun 26 00:25:47 CST 2021, time=2021-06-26, status=1, ipAttribution=)]
2021-06-26 ms6000000079288216

学习了，有用

93 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

晚期结直肠癌治疗：ASCO资源分层指南 2020

相关指南

科室

工具

服务